IRIS
MAFFIOLI, PAMELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.067
EU - Europa 4.807
AS - Asia 4.640
SA - Sud America 456
AF - Africa 53
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 2
Totale 16.040
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.937
CN - Cina 3.283
IE - Irlanda 1.176
UA - Ucraina 922
DE - Germania 726
FI - Finlandia 662
HK - Hong Kong 662
RU - Federazione Russa 494
SG - Singapore 450
BR - Brasile 402
IT - Italia 264
SE - Svezia 259
GB - Regno Unito 170
CA - Canada 100
IN - India 48
BD - Bangladesh 24
FR - Francia 24
NL - Olanda 22
ZA - Sudafrica 22
VN - Vietnam 21
MX - Messico 19
TR - Turchia 19
IR - Iran 16
ES - Italia 15
IQ - Iraq 15
JP - Giappone 14
AR - Argentina 12
PE - Perù 12
UZ - Uzbekistan 12
BE - Belgio 11
TH - Thailandia 10
CO - Colombia 9
MU - Mauritius 9
PL - Polonia 9
EC - Ecuador 8
VE - Venezuela 8
AT - Austria 7
AU - Australia 7
IL - Israele 7
JO - Giordania 7
NZ - Nuova Zelanda 7
RO - Romania 7
DZ - Algeria 6
MY - Malesia 5
PK - Pakistan 5
AZ - Azerbaigian 4
BH - Bahrain 4
EE - Estonia 4
EG - Egitto 4
GR - Grecia 4
KE - Kenya 4
KG - Kirghizistan 4
KR - Corea 4
PT - Portogallo 4
TN - Tunisia 4
CH - Svizzera 3
HU - Ungheria 3
KZ - Kazakistan 3
LV - Lettonia 3
MA - Marocco 3
OM - Oman 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
EU - Europa 2
GE - Georgia 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LT - Lituania 2
MD - Moldavia 2
NI - Nicaragua 2
PA - Panama 2
QA - Qatar 2
RS - Serbia 2
SA - Arabia Saudita 2
BG - Bulgaria 1
BY - Bielorussia 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
GT - Guatemala 1
HN - Honduras 1
IM - Isola di Man 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
MK - Macedonia 1
NO - Norvegia 1
NR - Nauru 1
PH - Filippine 1
PS - Palestinian Territory 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 16.039
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.326
Dublin 1.176
Chandler 1.053
Nanjing 999
Hong Kong 662
Boardman 430
Nanchang 421
Ashburn 335
Shenyang 296
Hebei 283
Princeton 283
Lawrence 275
Medford 267
Wilmington 253
Beijing 249
Changsha 248
Jiaxing 218
Singapore 180
Hangzhou 170
Munich 165
Helsinki 153
Tianjin 144
Moscow 89
Toronto 70
Cambridge 54
Ann Arbor 53
Woodbridge 49
Milan 48
Seattle 47
Los Angeles 46
Shanghai 45
Fairfield 33
Norwalk 33
São Paulo 29
Des Moines 23
Jinan 23
Kunming 21
Turku 20
Bruino 19
Pavia 19
Genova 17
New York 16
San Francisco 16
The Dalles 16
Zhengzhou 16
Johannesburg 15
Pune 15
Belo Horizonte 14
Falkenstein 13
Orange 13
Piscataway 13
Rio de Janeiro 13
Tokyo 13
Guangzhou 12
Ningbo 12
Tashkent 12
Brooklyn 11
Salvador 10
Brussels 9
Chicago 9
Eindhoven 9
Lima 9
Montreal 9
Santa Clara 9
Campinas 8
Dhaka 8
Phoenix 8
Stockholm 8
West Jordan 8
Amman 7
Bangkok 7
Bogotá 7
Bologna 7
Chennai 7
Fuzhou 7
Ho Chi Minh City 7
Redwood City 7
Secaucus 7
Taizhou 7
Washington 7
Columbus 6
Curitiba 6
Dallas 6
Lanzhou 6
Leawood 6
London 6
Nuremberg 6
Pioltello 6
Quận Bình Thạnh 6
Auckland 5
Berlin 5
Changchun 5
Dearborn 5
Erbil 5
Guarulhos 5
Hanoi 5
Houston 5
Paris 5
Redmond 5
Shah Alam 5
Totale 10.834
Salva come PNG Salva come JPEG
Nome #
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial 203
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial 156
A randomized, placebo-controlled study about the effect of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters 146
Diagnostico y Tratamiento de los desordenes lipidicos. Mc Graw Hill Education 2014. 105
A possible way to improve the glycemic control and the beta cell function during three years: the triple therapy. 98
Diarrea in paziente diabetico 97
A multicenter, randomised, single-blind study on the effects of exenatide or glimepiride on insulin resistance. 94
Differential effect of candesartan and olmesartan on adipose tissue activity biomarkers in type 2 diabetic hypertensive patients 93
Effects of berberis aristata/silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients 90
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients 90
A comparison between sitagliptin or glibenclamide in addition to metformin+pioglitazone on glycemic control and beta-cell function: the triple oral therapy 89
Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study 87
Different actions of losartan and ramipril on adipose tissue Activity and vascular remodeling biomarkers in hypertensive patients 87
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load 86
Comparison between exenatide and glimepiride on metabolic control and on insulin resistance in type 2 diabetic patients with metformin therapy 85
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients 84
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 83
Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. 83
Differenti effetti di candesartan e olmesartan sui parametri di attività del tessuto adiposo in pazienti diabetici di tipo 2 ipertesi 80
Adipocytokines levels in obese and non-obese subjects, an observational study 80
Confronto tra candesartan e olmesartan sui parametri correlati alla sensibilità insulinica nei pazienti ipertesi con diabete mellito di tipo 2 80
Acarbose compared to placebo on insulin resistance biomarkers in a double-blind, placebo-controlled trial 79
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study 78
A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients 77
Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients 77
A systematic reviewandmeta-analysis of randomized controlled trials investigating the effects of supplementationwith Nigella sativa (black seed) on blood pressure 77
Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus 76
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 76
n-3 PUFAs on metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients after euglycemic clamp and oral fat load. 76
Aerobic physical activity in obese subjects compared to anaerobic/aerobic physical activity 76
Effects of berberine on lipid profile in subjects with low cardiovascular risk 76
A randomized, double blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. 76
Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients 75
Effects of sibutramine plus L-carnitine compared to sibutramine on inflammatory parameters in type 2 diabetic patients 75
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone 74
Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin 73
Effetti di un anno di trattamento con vildagliptin associato a pioglitazone o glimepiride in pazienti diabetici scarsamente controllati 73
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis 73
A clinical trial about a food supplement containing α-lipoic acid on oxidative stress markers in type 2 diabetic patients 73
Effetti sulla variabilità glicemica e sul compenso glico-metabolico di metformina, pioglitazone e sitagliptin in pazienti affetti da diabete mellito di tipo 2 73
Effetti di un anno di trattamento con orlistat+L-carnitina paragonato a orlistat o placebo sui parametri di insulino-resistenza nei pazienti diabetici 72
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. 72
Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: A randomized, placebo-controlled, clinical trial. 72
Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. 72
Candesartan effect on inflammation in hypertension 71
Prevalence of erectile dysfunction in males affected by type 2 diabetes and the impact of hyperinsulinemia 71
Valutazione dell’infiammazione e delle MMPs nei soggetti con e senza diabete durante OGTT 71
Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study 70
Anti-obesity drugs: a review about their effects and their safety 70
Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. 70
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients 70
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus 70
Effect of manidipine-rosuvastatin combination on fibrinolysis, inflammation markers and insulin sensitivity in hypertensive hypercholesterolemic patients 69
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients 68
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 68
Valutazione dei livelli di metalloproteasi 2 e 9 e dei loro inibitori nei soggetti con dislipidemia combinata 68
A curious case of hypoglycaemia 68
Olmesartan/amlodipine combination vs olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients 68
Prevalence and associations of erectile dysfunction in a sample of italian males with type 2 diabetes. 68
Effetti di sitagliptin o metformina associati a pioglitazone in pazienti diabetici scarsamente controllati 68
A review about biomarkers for the investigation of vascular function and impairment in diabetes mellitus 68
Matrix metalloproteinase-2 and – 9 levels in obese patients 67
Effetti di un carico lipidico orale sui marcatori di infiammazione e stress endoteliale nei soggetti sani 67
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 67
Metformina in bustine rispetto a metformina nella classica formulazione in compresse: primi risultati di uno studio clinico 67
Hypoglycemia, its implications in the clinical practice, and possible ways to prevent it. 67
Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. 67
A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk 67
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients 66
Impact of the glyco-metabolic control on erectile dysfunction in patients with type 2 diabetes mellitus 66
Effetti di un carico lipidico orale sui marcatori di rimodellamento vascolare nei soggetti sani 66
Current and emerging pharmacotherapies for the management of hypertension, focus on aliskiren 66
Rosiglitazone maleate and glimepiride in fixed combination for the metabolic control of type 2 diabetes 66
Sitagliptin in aggiunta alla precedente terapia ipoglicemizzante sull'insulino-resistenza e il profilo lipidico: uno studio a due anni 66
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia during omega-3 polyunsaturated fatty acids therapy 65
Effetto del telmisartan sui marcatori infiammatori a digiuno e postprandiale nei pazienti diabetici ipertesi 65
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 65
Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients 65
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes 64
Effetti di un anno di trattamento con exenatide paragonato a glibenclamide in pazienti diabetici di tipo 2 64
Effetti della formulazione idrosolubile di metformina sul compenso glicemico e sulla qualità della vita in pazienti con diabete mellito di tipo 2 64
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 64
Pharmacotherapy for Obesity 64
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. 64
Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study 63
Exenatide or glimepiride on insulin resistance in type 2 diabetic patients 63
Evaluation of candesartan compared to olmesartan on insulin sensitivity-related parameters in type 2 diabetic hypertensive patients 63
Effetti della combinazione Berberis aristata/Silybum marianum sul profilo lipidico e la secrezione insulinica in pazienti con basso rischio cardiovascolare 63
Effects of berberine on lipid profile in subjects with low cardiovascular risk 63
Effects of an olmesartan/amlodipine combination compared to olmesartan or amlodipine monotherapies on some insulin resistance parameters in hypertensive patients 63
A randomized, double blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetic patients already treated with pioglitazone and metformin: a three years study 63
Effects of thiazolidinediones and sulfonylureas in patients with diabetes 62
Comparative effect of amlodipine and amlodipine plus aliskiren on insulin sensitivity and inflammatory parameters in the treatment of hypertension in patients with metabolic syndrome 62
Pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina durante un carico orale di grassi 62
Evaluation of candesartan compared to olmesartan on insulin-sensitivity related parameters in type 2 diabetic hypertensive patients 62
L'importanza di rimettere in discussione una diagnosi già fatta 62
Safety and efficacy of albiglutide-results from two trials 62
Effects of sibutramine plus L-carnitine compared to sibutramine or placebo on inflammatory parameters 62
Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials 62
Effect of acarbose on inflammatory parameters at baseline and after an oral fat load: a double-blind, placebo controlled trial 61
Totale 7.500
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.535
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.535
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.754 221 170 39 176 2 217 8 319 46 286 225 45
2021/20221.031 9 4 65 9 4 6 8 58 59 7 175 627
2022/20233.250 358 193 6 221 372 348 2 198 1.370 40 94 48
2023/20241.058 120 196 37 73 121 257 16 120 9 33 37 39
2024/20253.371 24 329 98 110 70 89 246 284 718 77 368 958
2025/2026230 230 0 0 0 0 0 0 0 0 0 0 0
Totale 16.387